Overview

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

Status:
Active, not recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.
Details
Lead Sponsor:
Bayer
Treatments:
Radium Ra 223 dichloride